Global Head Of Dmpk
Current
Mar 2023 - Present
AeroLeads people directory · profile
Alison Betts Email & Phone Number
Global head of DMPK & Modeling
at
Takeda
1 work email found
@takeda.com
LinkedIn matched
✓ Verified August 2026
4 data sources
Profile completeness 100%
Who is Alison Betts? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Alison Betts is listed as Global head of DMPK & Modeling at Takeda, based in Greater Boston, United States. AeroLeads shows a work email signal at takeda.com and a matched LinkedIn profile for Alison Betts.
Alison Betts previously worked as Global Head of DMPK at Takeda and Vice President Scientific Collaborations, Fellow of Modeling & Simulation at Applied Biomath. Alison Betts holds Doctor Of Philosophy - Phd, Quantitative Systems Pharmacology from Leiden University.
Company email context
Email format at Takeda
This section adds company-level context without repeating Alison Betts's masked contact details.
{first}.{last}@takeda.com
86% confidence
AeroLeads found 1 current-domain work email signal for Alison Betts. Compare company email patterns before reaching out.
Profile bio
About Alison Betts
Modeling and Simulation leader with extensive experience in application of quantitative systems pharmacology (QSP) and PK/PD models across a diverse range of therapeutic areas in the global pharmaceutical industry.Strong scientific and multi-disciplinary team leadership experience. Excellent team building and communication skills.Versatile, creative and skilled mathematical modeler with specific expertise in mechanistic modeling of complex biotherapeutic modalities. Hands-on experience of several modeling and simulation software including: Matlab, Monolix, Berkeley Madonna, Phoenix, NONMEM and GastroPlus Broad knowledge of the implementation of Drug Metabolism and Pharmacokinetics across drug discovery and development.Specialties:- Quantitative systems pharmacology (QSP), multi-scale mechanistic, and PK/PD modeling.- Pharmacokinetics (PK), Physiologically based PK (PBPK) modeling- Translational modeling of biotherapeutic drugs for oncology- particularly therapeutic antibodies, bispecific antibodies, Antibody Drug Conjugates (ADCs) and T-cell engagers (TCEs).- Pharmaceutical research.
Listed skills include Pharmacokinetics, Drug Discovery, Drug Metabolism, Drug Development, and 16 others.
Current workplace
Alison Betts's current company
Company context helps verify the profile and gives searchers a useful next step.
10 roles
Alison Betts work experience
A career timeline built from the work history available for this profile.
Global Head Of Dmpk & Modeling
Current
Mar 2023 - Present
Vice President Scientific Collaborations, Fellow Of Modeling & Simulation
Mar 2021 - Mar 2023
Senior Director
Sr. Director of Scientific Collaborations, Fellow of Modeling & Simulation
Jul 2019 - Mar 2021
Research Fellow
Apr 2019 - Mar 2021
Associate Research Fellow
• Translation modeling and simulation team leader, supervising a team of modelers providing translational quantitative systems pharmacology (QSP) modeling and strategic direction to all large molecule oncology programs in the Pfizer portfolio.• Provide guidance in the selection of compounds and viability of targets from idea to proof of concept.• Use Modeling and Simulation tools to provide quantitative multi-scale predictions of pharmacokinetics, biomarker endpoints and clinical efficacious dose.• Recognized global leader/expert in PK/PD modeling of large molecules at Pfizer; established large molecule PK prediction guidance and platform PK/PD and PBPK models for a range of biotherapeutic modalities including mAbs, antibody-drug conjugates, diabodies, scfvs, proteins and peptides; facilitating quantitative decision making across a wide range of RUs.• Recognized expert in quantitative modeling of Antibody Drug Conjugates. Provide scientific direction and guidance on ADCs externally as a frequent invited speaker at scientific meetings and symposia.• Specialize in QSP modeling of immune-oncology drugs including T-cell retargeting modalities and checkpoint inhibitors.
Mar 2016 - Mar 2019
Associate Research Fellow
• Oncology Research Unit Modeling and Simulation lead, within department of Pharmacokinetics, Dynamics and Metabolism.• PK/PD team leader providing PK/PD modeling and translational pharmacology strategic direction to the Biologics section of the Oncology Research Unit. • Provide guidance in the selection of compounds and viability of targets from idea to proof of concept.• Use Modeling and Simulation tools to provide quantitative multi-scale predictions of pharmacokinetics, biomarker endpoints and efficacious dose.• Leader of the Pfizer Biotherapeutics Modeling and Simulation Working Group which has successfully implemented platform PK/PD and PBPK models for a range of biotherapeutic modalities including mAbs, CovX bodies, antibody-drug conjugates, oligonucleotides and nanobodies, facilitating quantitative decision making across a wide range of RUs.• Recognized expert in quantitative modeling of Antibody Drug Conjugates.
Jan 2012 - Mar 2016
Senior Principal Scientist
• PK/PD team leader responsible for the successful execution of PK/PD modeling and translational strategy across the Antibacterials portfolio including projects from exploratory stage through to Phase 1 clinical development.• Identified business need and implemented new translational pharmacology strategies including increased use of in vitro tools and time course modeling of in vitro and in vivo antibacterial data.• Established in vitro: in vivo correlations so that in vitro models could be used to predict in vivo outcomes. This work resulted in a reduction in in vivo animal spend by 40%. Awarded Pfizer Animal Care and Welfare Board ‘Reduce, Re-use and Refine’ award 2010.• Implemented mechanism based PK/PD, PBPK and systems pharmacology models to predict efficacy and emergence of resistance and used these to develop novel strategies for clinical dose predictions of antibacterial drugs.• Leader of the cross-line Translational Pharmacology Team which was awarded a Pfizer Leadership Team Excellence Award 2009.• Established multiple external partnerships with leading anti-infective PK/PD groups, including University of Buffalo and ABRU Translational Medicine alliance, Ordway Research Institute of Infectious Diseases and ICPD) resulting in the advancement of PK/PD modeling in infectious diseases and its application to augment antibacterial drug discovery.
Jan 2009 - Dec 2011
Principal Scientist
Sep 2007 - Dec 2008
Prinicpal Scientist
Oct 1994 - Sep 2007
2 education records
Alison Betts education
Doctor Of Philosophy - Phd, Quantitative Systems Pharmacology
Leiden University
Bachelor Of Science - Bs, Biochemistry
University Of St Andrews
FAQ
Frequently asked questions about Alison Betts
Quick answers generated from the profile data available on this page.
What company does Alison Betts work for?
Alison Betts works for Takeda.
What is Alison Betts's role at Takeda?
Alison Betts is listed as Global head of DMPK & Modeling at Takeda.
What is Alison Betts's email address?
AeroLeads has found 1 work email signal at @takeda.com for Alison Betts at Takeda.
Where is Alison Betts based?
Alison Betts is based in Greater Boston, United States while working with Takeda.
What companies has Alison Betts worked for?
Alison Betts has worked for Takeda, Applied Biomath, and Pfizer.
How can I contact Alison Betts?
You can use AeroLeads to view verified contact signals for Alison Betts at Takeda, including work email, phone, and LinkedIn data when available.
What schools did Alison Betts attend?
Alison Betts holds Doctor Of Philosophy - Phd, Quantitative Systems Pharmacology from Leiden University.
What skills is Alison Betts known for?
Alison Betts is listed with skills including Pharmacokinetics, Drug Discovery, Drug Metabolism, Drug Development, Biomarkers, Pharmacology, Clinical Development, and Adme.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial